Adlai Nortye Ltd. American Depositary Shares (ANL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) has a cash flow conversion efficiency ratio of -0.266x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.19 Million) by net assets ($53.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Adlai Nortye Ltd. American Depositary Sh to measure how many days the company can operate on defensive assets alone.
Adlai Nortye Ltd. American Depositary Shares - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adlai Nortye Ltd. American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adlai Nortye Ltd. American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guolin Environmental Tech Co Ltd
SHE:300786
|
0.001x |
|
Echo Investment SA
WAR:ECH
|
0.140x |
|
Ovzon AB
ST:OVZON
|
0.041x |
|
Grupo Supervielle S.A
F:189A
|
0.176x |
|
JL MAG RARE-EARTH H YC1
F:3KLA
|
N/A |
|
SmartFinancial, Inc.
NASDAQ:SMBK
|
0.031x |
|
Yoantion Industrial Inc.Ltd.
SHE:301053
|
N/A |
|
HelloFresh SE
XETRA:HFG
|
0.201x |
Annual Cash Flow Conversion Efficiency for Adlai Nortye Ltd. American Depositary Shares (2019–2025)
The table below shows the annual cash flow conversion efficiency of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ANL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-8.32 Million | $-33.54 Million | 4.030x | +298.21% |
| 2024-12-31 | $25.48 Million | $-51.82 Million | -2.033x | -169.35% |
| 2023-12-31 | $75.05 Million | $-56.65 Million | -0.755x | -521.42% |
| 2022-12-31 | $-241.29 Million | $-43.22 Million | 0.179x | +994.79% |
| 2021-12-31 | $-185.43 Million | $-3.03 Million | 0.016x | -93.78% |
| 2020-12-31 | $-131.56 Million | $-34.59 Million | 0.263x | +22.25% |
| 2019-12-31 | $-69.38 Million | $-14.92 Million | 0.215x | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more